People
The company’s head of Development, Joerg Moeller, is taking the reins of the company’s new R&D program.
Ms. Kinjerski is a senior business development executive with more than 17 years of experience in the biopharmaceutical industry,
Since taking over at Teva earlier this fall, Kare Schultz has been swiftly moving to shore up the finances and pay down the massive debts of the beleaguered pharmaceutical company.
Shawver, a long-time industry veteran, will assume the role of president, CEO and director of Synthorx.
Mr. Hartman overviewed the Company’s Anti-Cancer R&D program and discussed his intent to find a licensee for the technology or investment partner to complete the development of this very promising anti-cancer antibody drug.
A look at six bay area-based VCs who are creating a lot of value in biotech.
Azar, the new HHS nominee, is being pitched as someone who will help lower the price of prescription drugs.
Every year, Forbes creates lists of “30 Under 30" leaders in various industries who are under the age of 30.
Alex Azar was head of U.S. operations for Lilly until January.
PRESS RELEASES